Multiplate-Analysis as prognostic marker in cerebral hemorrhage

Multiplate-Analysis as prognostic marker in cerebral hemorrhage - Multiplate-2020

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021725

Enrollment

150

Registered

2021-03-02

Start date

2021-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracerebral hemorrhage Subdural hemorrhage Subarachnoidal hemorrhage I61 I62 I60

Interventions

Group 1: Patients with hemorrhagic stroke - pre-existing therapy with antiplatelet medication intended examinations: at admission: - cranial CAT-Scan (during first care at the ER, independent of the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Signed declaration of consent + blood samples - Age over 18 years - proven intracerebral hemorrhage (CT/MRT) - Ingestion of at least 1 platelet function inhibitor (test group) - Unequivocal understanding of the information provided about the study

Exclusion criteria

Exclusion criteria: - No image correlate of the initial neurological symptoms - Competing prognostic factors at the onset of symptoms: e.g. medication, metabolic derailments, sepsis - Persons who are in a dependency / employment relationship with one of the investigators - Minority - Pregnancy and breastfeeding - People who are accommodated in an institution by order of a court or an official - Simultaneous participation in a clinical study - unwilling or unable to understand the instructions of the staff or to obey them - incapable of giving consent and / or are unable to understand the nature, significance and scope of the research project and to give their consent

Design outcomes

Primary

Measure	Time frame
Progress of the bleeding Procedure: 1) Comparison of the size of the bleeding between the CAT-Scan at admission and the follow-up CAT-Scan (24-48 hours later) in both arms (measurement of the bleeding size in the program for image processing used by the department of neuroradiology) 2) Statistical evaluation if there was a significant difference in bleeding enlargement between the group with pre-existing antiplatelet therapy and the group without pre-existing antiplatelet therapy	—

Measure

Time frame

Progress of the bleeding Procedure: 1) Comparison of the size of the bleeding between the CAT-Scan at admission and the follow-up CAT-Scan (24-48 hours later) in both arms (measurement of the bleeding size in the program for image processing used by the department of neuroradiology) 2) Statistical evaluation if there was a significant difference in bleeding enlargement between the group with pre-existing antiplatelet therapy and the group without pre-existing antiplatelet therapy

—

Secondary

Measure	Time frame
therapy failure -> number of patients with pre-existing antiplatelet therapy but insufficient score in the Multiplate-analysis	—

Countries

Germany

Contacts

Public ContactJan Heckelmann

Universitätsklinikum der RWTH Aachen

jheckelmann@ukaachen.de0241-80 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026